Umeclidinium bromide NEW
| Price | $34 | $77 | $126 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Umeclidinium bromide | CAS No.: 869113-09-7 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Umeclidinium bromide |
| Description | Umeclidinium bromide (GSK573719A) is a novel mAChR antagonist. |
| Animal Research | Mice:Age-matched male BALB/c mice (23-25 gm) are pretreated intranasally (50 μL per mouse) with vehicle (0.9% saline) or Umeclidinium bromide at intervals (0.25-48 hours) prior to methacholine challenge, and placed into individual plethysmograph chambers. Fresh air is supplied by bias flow pumps to the chambers. After baseline respiratory [enhanced pause (Penh)] values are collected, the mice received methacholine (30 mg/mL or EC80) by aerosol delivery (flow=1.6 mL/min×2 minutes). An average Penh is then calculated for 5 minutes. Penh=[(expiratory time/relaxation time)?1]×(peak expiratory flow/peak inspiratory flow), and relaxation time is the amount of time required for 70% of the tidal volume to expire. In some cases, animals are treated on multiple, consecutive days as described in the figure legends. The data are expressed as the mean±S.E.M. percent inhibition of Penh or (mean Penh value of vehicle treated group-Penh for each drug-treated animal) divided by (mean Penh value of vehicle treated group)×100%. Data are analyzed using commercially available software. |
| In vitro | In human embryonic kidney 293 cells, Umeclidinium bromide (GSK573719A) inhibits the human ether-a-go-go-related gene channel tail current in a concentration-dependent manner (IC50 = 9.4 μM). |
| In vivo | Administering Umeclidinium bromide (GSK573719A) intranasally at a dose of 0.025 μg to mice once daily for five days incrementally enhances its inhibitory effect on bronchomotor tone, with inhibition increasing from 35% after the first dose to 60% by the fifth day. Following a five-day rest period, where bronchomotor tone reverts to baseline, a subsequent dose yields an inhibition level comparable to that of the initial dose, indicating the absence of tolerance development with repeated intranasal administration. Conversely, oral administration of Umeclidinium bromide at 2.0 mg/kg, equivalent to 100 times the intranasal ED50 value, fails to offer any protective effect against an Mch challenge, demonstrating the method-specific efficacy of this compound. |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 83.3 mg/mL (163.82 mM), Sonication is recommended. 10% DMSO+90% Saline : 8.33 mg/mL (16.38 mM), Solution. |
| Keywords | Umeclidinium bromide | Umeclidinium | Muscarinic acetylcholine receptor | mAChR | M5 mAChR | M4 mAChR | M3 mAChR | M2 mAChR | M1 mAChR | Inhibitor | inhibit |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Ethyl (triphenylphosphoranylidene) acetate | Urethane | Hexamethonium Bromide | Ribavirin | Adenine | Mitotane | Choline chloride | Propoxur | N,N-Dicyclohexylcarbodiimide | Arecoline |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Parkinson's Disease Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-03 | |
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-07-02 | ||
| $124.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-05-15 | |
| $70.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
| $100.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | ||
| $10.00 |
Wuhan Xinhao Biotechnology Co., Ltd
|
2024-04-02 | ||
|
PNP Biotech Co. Ltd
|
2024-03-28 | |||
| $10.00 |
Anhui Zhongda Biotechnology Co., Ltd
|
2023-11-03 | ||
| $30.00 |
Wuhan wingroup Pharmaceutical Co., Ltd
|
2023-07-19 | ||
| $280.00 |
Hebei Mingeng Biotechnology Co., Ltd
|
2023-06-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY